Inherent intermediate-to low-affinity T-cell receptors (TCR) that develop during the natural course of immune responses may not allow sufficient activation for tumor elimination, making the majority of T cells suboptimal for adoptive T-cell therapy (ATT). TCR affinity enhancement has been implemented to provide stronger T-cell activity but carries the risk of creating undesired cross-reactivity leading to potential serious adverse effects in clinical application. We demonstrate here that engineering of low-avidity T cells recognizing a naturally processed and presented tumor-associated antigen with a chimeric PD-1:28 receptor increases effector function to levels seen with high-avidity T cells of identical specificity. Upgrading the function of low-avidity T cells without changing the TCR affinity will allow a large arsenal of low-avidity T cells previously thought to be therapeutically inefficient to be considered for ATT. PD-1:28 engineering reinstated Th1 function in tumor-infiltrating lymphocytes that had been functionally disabled in the human renal cell carcinoma environment without unleashing undesired Th2 cytokines or IL10. Involved mechanisms may be correlated to restoration of ERK and AKT signaling pathways. In mouse tumor models of ATT, PD-1:28 engineering enabled low-avidity T cells to proliferate stronger and prevented PD-L1 upregulation and Th2 polarization in the tumor milieu. Engineered T cells combined with checkpoint blockade secreted significantly more IFNg compared with T cells without PD-1:28, suggesting a beneficial combination with checkpoint blockade therapy or other therapeutic strategies. Altogether, the supportive effects of PD-1:28 engineering on T-cell function make it an attractive tool for ATT. Cancer Res; 77(13); 3577-90. Ó2017 AACR.
Introduction
Magnitude, quality, and functional polarization of an immune response are crucial for the control of many diseases, including cancer. Examples of successful implementation of these principles are the adoptive transfer of selected highly tumor-reactive T cells
(1) and checkpoint inhibition (2) , which achieve remarkable tumor regressions even in patients who have failed previous treatments. Despite these successes, immunotherapeutic concepts need to be improved as no or low response is still a frequent outcome. Although there is consensus that durable antitumor responses require highly active T cells, it is not clear how this is best achieved. At least two major impediments have been identified that impinge upon achieving this prerequisite: inherent intermediate-to low-affinity T-cell receptors (TCR) of antitumor T cells that may not mount a successful tumor-specific response (3, 4) , and functional inactivation of T cells in the tumor milieu (5) (6) (7) (8) .
Experimentally generated high-affinity TCRs might be advantageous by boosting effector function and proliferation, thereby persisting longer and in larger numbers as compared with T cells with low-affinity TCRs, but they may also bear an increased risk of unwanted toxicities (3, 4, (9) (10) (11) (12) . Low-avidity T cells would gain value if their effector functions could be enhanced, as they are reported to be less susceptible to tolerization and may represent a lower toxicity risk (3, 4, 13, 14) .
Loss of function following tumor infiltration occurs independently of T-cell avidity (5) (6) (7) (8) . Thus, preventing or delaying functional loss and endowing reactive T cells with the capacity to maintain antitumor effector functions longer in the tumor environment are imperatives for achieving more effective T-cell response. Functional inactivation may occur due to blockade of TCR signaling, loss of cytotoxic proteins, lack of persistence, and functional polarization from an antitumor Th1 to a less favorable Th2 phenotype (15) (16) (17) (18) (19) (20) (21) .
To overcome these activation restrictions, we focused on costimulation and coinhibition signals controlling strength and duration of the T-cell response (22) . In challenging environments, costimulation has been shown to improve effector function as it enables refill of lytic granules and T-cell expansion (23, 24) . Thus, we generated chimeric receptors composed of the PD-1 extracellular domain and the CD28 signaling domain (PD-1:28) following published designs (25, 26) . PD-1:28-engineered T cells should receive costimulatory signals to support survival, proliferation, and TCR signaling when interacting with PD-1 ligand (PD-L1) on tumor cells. Simultaneously, coinhibitory interaction with expressed native PD-1 should be opposed, ameliorating another major hurdle of efficient antitumor function in PD-L1 þ tumor milieus. All this will occur without changing the TCR specificity.
Here, we demonstrate that PD-1:28 chimeric receptors upgrade low-avidity T cells and restore effector function of tumor-suppressed human tumor-infiltrating lymphocytes (TIL). Through PD-1:28 signaling, T cells receive support in processes essential for tumor growth control, that is, stronger proliferation in solid tumor milieus and prevention of Th2 polarization. Moreover, PD-1:28-facilitated T-cell support seems to work synergistic with anti-PD-L1 checkpoint blockade, suggesting that PD-1:28 engineering of T cells can be beneficially combined with checkpoint blockade and potentially other immunotherapies.
Materials and Methods

Cell lines, PBMCs, and TILs
Cell lines were grown in RPMI1640/1% L-glutamine/1% nonessential amino acids/1% sodium pyruvate/1% penicillin/streptomycin (RPMI basic), and 12% FCS at 37 C/6.5% CO 2 . Cell lines were kept in continuous culture for no longer than 2 months. Mycoplasma testing was performed monthly using VenorGeM Classic (Minerva Biolabs). All cell lines were authenticated by flow cytometry to express the relevant molecules, HLA-A2, tyrosinase or TCR53 antigen, without or with PD-L1, as required (see Results). The following cell lines were used: HEK293 cells (positive for HLA-A2, negative for endogenous PD-L1 by flow cytometry, obtained from H. Engelmann, Institute of Immunology, Munich, Germany, in 1997) were transduced in our laboratory to express tyrosinase (HEK/Tyr) or tyrosinase and PD-L1 (HEK/Tyr/PD-L1). Single-cell clones were selected for comparable HLA-A2 and tyrosinase expression (see Results Murine hepatocellular carcinoma (HCC) line 434 originated in LoxP-TAg mice (28) and was grown in RPMI-basic/12% FCS/0.05% b-mercaptoethanol (mouse medium). Authentication was done by testing SV40LT, H2-D b , and PD-L1 expression. Human peripheral blood mononuclear cells (PBMC) were from healthy donors (HD). Transduced T cells were grown in RPMI-basic/10% human serum (T-cell medium) and 50 U/mL IL2, or as indicated. TILs were tissue suspensions prepared from postsurgery clear cell renal cell carcinoma (ccRCC) as described previously (16) . Detailed pathologic features are described in Supplemental Material. Blood and tissues were collected with donors' and patients' informed consent in accordance with the Declaration of Helsinki and after approval by the Institutional Review Board of Ludwig-Maximilian University (Munich, Germany).
Constructs, expression vectors, electroporation, and retroviral transduction pMP71 plasmids encoding TCR-T58, TCR-D115 (both tyrosinase-epitope(AA 366-377 )-specific/HLA-A2-restricted), and TCR53 have been described previously (27) . Various costimulatory chimeric receptors were designed on the basis of the extracellular domain (ECD) of PD-1 and the intracellular domain (ICD) of CD28 containing the signaling motifs YMNM, PRRP, and PYAP (Fig. 1A) . The chimeric sequence PD-1:8 tm :28 was composed of PD-1 ECD (AA1-170), CD8a (AA128-210) as linker and transmembrane domain (TMD), followed by CD28 ICD (AA180-220). PD-1:cys28 tm contains PD-1 ECD (AA1-155) followed by CD28 TMD-ICD (AA141-220), which includes the membrane-proximal cysteine residue at position AA141 (adapted from Prosser and colleagues; ref. tm contains murine PD-1 ECD (AA1-169) and murine CD28 TMD-ICD (AA151-218). Chimeric sequences were ordered from GeneArt.
Chimeric receptors were expressed in human T cells either by electroporation with in vitro-transcribed RNA cloned in pGEM vector (provided by S. Milosevic, Medigene GmbH) or by retroviral transduction using the pMP71 vector as described previously (29) . Murine splenocytes were retrovirally transduced as described previously (29) . For experimental details, see Supplementary Material.
Human melanoma xenograft and murine HCC models
The animal experiments were performed according to and with approval of the Landesamt f€ ur Gesundheit und Soziales, Berlin, Germany (HCC model) or they were approved by the Regierung von Oberbayern, Germany and performed in accordance with the Animal Care and Use Committee at the Helmholtz Zentrum M€ unchen (NSG model).
For the xenograft model, NSG mice (Charles River Laboratories; 7-11 weeks old) were injected subcutaneously with 5 Â 10 6 SK-Mel23 cells. Grown to approximately 800 mm 3 (15-20 days), tumors were injected intratumorally with 6 Â 10 6 carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled T cells. Tumors were harvested and weighed 4 hours, 1, 2, 4, 6, and 10 days after adoptive T-cell therapy (ATT). Single-cell suspensions were prepared for flow cytometry as described previously (16) . Tumors were measured using a caliper prior to T-cell injection and before mice were sacrificed. Tumor volumes were calculated using the formula; volume ¼ (length Â width 
Multiparameter flow cytometry and FACS sorting of TILs
Flow cytometry was performed with LSRII (BD Biosciences) and FlowJo 8.8.7 software. PD-1:28 chimeric receptor and transgenic TCRs (TCR-T58, TCR-D115) expression was analyzed using anti-PD-1-APC (eBioscience), anti-mouse TCRb-constant region (mTCR)-PB (BioLegend), anti-CD3-PE-Cy7 (BioLegend), anti-CD4-APC-A780 (eBioscience), anti-CD8-V500 (BD), anti-Ki-67-Alexa-Fluor-700 (BioLegend), anti-PD-L1-BV421 (BD Biosciences), and 7-AAD (Sigma-Aldrich). Absolute cell numbers of intratumoral T cells were determined using Flow-Count Fluorospheres (Beckman Coulter). HEK293 and tumor lines were analyzed using anti-HLA-A2 (ATCC HB54) plus anti-mouse IgG1-A488 (Invitrogen), anti-PD-L1-FITC (BD Biosciences), anti-tyrosinase (Upstate Biotechnology) plus anti-mouse IgG2a-A647 (Invitrogen), and 7-AAD. T cells were stimulated with HEK/Tyr/PD-L1 cells at 1:2 (30 minutes/37 C), then stained with anti-CD45-PE-Cy7 (BioLegend), anti-CD8-V500, anti-pERK (pT202/pY204; Cell Signaling Technology) plus anti-rabbit IgG-A647 (Invitrogen) or anti-pRPS6 (pS235/pS236)-A647 (Cell Signaling Technology), and 7-AAD. Cells were fixed using Phosflow Cytofix Buffer (BD Biosciences) and permeabilized with Phosflow Perm Buffer III (BD Biosciences).
T cells from NSG xenograft tumors were analyzed using anti-CD45-PE-Cy7, anti-CD8-PB (BD Biosciences), anti-PD-1-APC, and 7-AAD. TILs and splenocytes from mice HCC tumors were stained using anti-CD3-APC-Cy7 (BioLegend), anti-CD19-V450 (eBioscience), anti-CD45-PE-Cy7 (eBioscience), anti-PD-1-PerCP-Cy5.5 (BioLegend), anti-Thy1.1-A647 (BioLegend), and propidium iodide (Sigma-Aldrich).
Tumor suspensions from ccRCC were stained with anti-CD45-PE-Cy7, anti-CD3-PB (both BioLegend), anti-CD11c-APC, and near-IR fluorescence-reactive viability dye (Invitrogen) and sorted as CD45 Tumor spheroids and microscopic imaging Spheroids were generated by seeding 800 SK-Mel23 cells into hanging drops. On day 3, single spheroids were confronted with 1.5 Â 10 4 T cells labeled with CMFDA (Thermo Fisher Scientific) for 30 minutes. Nonattached T cells were removed and T cells/spheroids incubated in hanging drops with CellEvent Caspase-3/7 Red Detection Reagent (Thermo Fisher Scientific) for 24 hours followed by fixation. Samples were imaged up to a depth of 70 mm using a spinning disk confocal Nikon TiE microscope. Invaded CMFDA þ T cells and CellEvent Caspase-3/7-positive apoptotic cells were counted using Fiji software (see Supplementary Material for details).
Chromium release assay
Chromium release assay was performed as described previously (16) .
Statistical analysis
Statistical tests, indicated in figure legends, were performed using GraphPad Prism 6 software.
Results
PD-1:28 chimeric receptor expression depends on the origin of the transmembrane domain
To facilitate costimulation of T cells in tumor environments, we designed costimulatory chimeric receptors encompassing the ECD of PD-1 and the ICD of CD28. Different receptor designs ( 
PD-1:cys28
tm and PD-1:28 tm augment T-cell cytokine secretion and signaling
Effects of chimeric receptors on T-cell function were analyzed by assessing TCR-induced cytokine secretion. Human T cells were transduced to stably express one of two different HLA-A2-restricted tyrosinase-specific TCR, T58 or D115, followed by transient expression of chimeric costimulatory receptor ( Fig. 2A) . These T cells were stimulated with HLA-A2 þ HEK293 cells expressing either the target antigen tyrosinase (HEK/Tyr) alone or together with PD-L1, the ligand for PD-1 (HEK/Tyr/PD-L1; Fig. 2B ). Despite artificial expression of tyrosinase, HEK/Tyr cells were low activators of TCR-T58-or TCR-D115-T cells stimulating less IFNg secretion and lower cytotoxicity than the natural tumor target SK-Mel23 ( Fig. 2C-E) . The HEK-cell system was further used as it allowed assessing the contribution of PD-L1 interacting with PD-1:28 chimeric receptors to T-cell function. TCR-T58-and TCR-D115-expressing T cells with PD-1:28 tm or PD-1:cys28 tm secreted significantly more IL2 and IFNg when stimulated with HEK/Tyr/PD-L1 compared with HEK/Tyr cells (Fig. 3A) . The PD-1:8 tm :28 chimeric receptor had no effect on IL2 and IFNg production of T cells expressing either transgenic TCR. Expression of PD-1trunc did not alter cytokine secretion of TCR-T58-T cells, but increased cytokine secretion of TCR-D115-T cells when stimulated with HEK/Tyr/PD-L1 cells, indicating that the truncated PD-1 is not an inert construct. The effect is likely due to competitive attenuation of negative signals through T cell-upregulated native PD-1 interacting with PD-L1 on target cells. Therefore, T cells electroporated with water (control) must be the reference for experiments assessing PD-1:28 effects.
To demonstrate that improved function was due to specific ligand receptor binding, blocking antibodies to PD-1 and PD-L1 were added to cocultures. No effect was seen in cocultures of untransfected T cells with HEK/Tyr or HEK/Tyr/PD-L1 cells. Similarly, no effect was seen when PD-1:28 tm T cells were cocultured with HEK/Tyr cells. However, when blocking antibodies were added to cocultures of PD-1:28 tm T cells with HEK/Tyr/PD-L1 cells, cytokine levels were reduced to those in HEK/Tyr cocultures, thus representing the levels induced by the TCR alone (Fig. 3B) .
The molecular basis for the significant increase in cytokine secretion upon stimulation through PD-1:28 tm was investigated by assessing phosphorylation of MAP kinase ERK and ribosomal protein S6 (RPS6) using phospho-flow cytometry. After stimulation with HEK/Tyr/PD-L1, phosphorylation of ERK was enhanced 4.4-fold in PD-1:28 tm -engineered T cells compared with water control. Regarding pRPS6, 43% of PD-1:28 tm T cells were positive for the phosphorylated form compared with 33% in control ( Fig.  3C and D) . Although these differences were not significant, there was a clear and reproducible trend toward increased phosphorylation of both ERK and RPS6 when T cells received dual stimulation through PD-1:28 tm and their TCRs.
PD-1:cys28 tm and PD-1:28 tm upgrade low-avidity T cells to achieve cytokine secretion comparable with high-avidity T cells
Next, we assessed whether PD-1:28 engineering could improve functional responses of T cells with low-avidity TCRs recognizing tumor-expressed self-antigens.
T58 and D115 are high-and low-avidity TCRs, respectively, that recognize the same HLA-A0201-restricted tyrosinase epitope. Low-avidity TCR-D115-expressing T cells secreted significantly less IL2 and IFNg than T cells expressing TCR-T58 when stimulated with HEK/Tyr/PD-L1 target cells (Fig. 4A) (Fig. 4C , and data not shown). PD-L1 was strongly induced on SK-Mel23 grown as 3D spheroids, and significantly higher T-cell numbers and more apoptotic tumor cells were recovered from spheroids cocultured with PD-1:28 tm -engineered TCR-D115-T cells compared with TCR-D115-T cells without PD-1:28 tm (Fig. 4D ). Higher PD-L1 levels were also seen on nonmelanoma lines (FI range, 850-1830) that express the natural tumor antigen recognized by TCR53 (27) . Consistent with the PD-L1 expression on TCR53 target cells, TCR53-T cells derived strong benefit from PD-1:28 tm engineering with 1.4-to 2.5-fold improvement of IFNg secretion (Fig. 4E) . These results indicate that T cells will benefit more from PD-1:28 tm engineering in tumor milieus where PD-L1 is highly expressed.
PD-1:28 tm can reinstate function in unresponsive tumorinfiltrating T lymphocytes from human RCC and can work in synergy with checkpoint blockade therapy
We previously demonstrated that TILs from human RCC tissue show deficits in degranulation and IFNg secretion, in part due to insufficient activation of signaling molecules AKT, ERK, and JNK (16) . As CD28 costimulation fosters activation of intracellular signaling molecules, including AKT, ERK, and JNK, we sought to determine whether costimulation through PD-1:28 tm could restore functionality in unresponsive TILs. Therefore, sorted CD3 (Fig. 5A) . Similar improvement was observed for IL2 secretion (Fig. 5B) . As TILs in the tumor microenvironment can be polarized toward Th2 or regulatory IL10 programs, we addressed the question whether facilitated costimulation through PD-1:28 might unleash undesirable Th2 or IL10 cytokines. However, neither mock-transfected nor PD-1:28 tm -transfected TILs (n ¼ 3) secreted detectable levels of IL4, IL5, IL13, or IL10 (data not shown). These cytokines were detected at low levels in supernatants of one (IL4) and two (IL13) HD-PBMCs, yet levels were not augmented when costimulated through PD-1:28 tm . TNF levels in supernatants of TILs were very low and marginally increased after facilitated costimulation. HD-PBMCs secreted detectable amounts of TNFa; yet, levels did not change with PD-1:28 tm costimulation (data not shown). Thus, costimulation through PD-1:28 tm can reinstate functionality in TILs that had lost activity in the tumor microenvironment. Costimulation through PD-1:28 tm rescued Th1 cytokine secretion (IFNg, IL2), while TNFa, Th2 cytokines, or IL10 were not affected.
Presumably, ATT will be combined with checkpoint blockade using anti-PD-1 or anti-PD-L1 antibodies. To explore whether PD-1:28 tm -engineered T cells would benefit in this situation, we added titrated concentrations of anti-PD-L1 antibody to cocultures of TCR-D115/Mock or TCR-D115/PD-1:28 tm T cells with HEK/Tyr or HEK/Tyr/PD-L1 and measured secreted IFNg. Anti-PD-L1 antibody did not change IFN-g levels if the target cell was negative for PD-L1 (Fig. 5C) 
PD-1:28 tm fosters intratumoral T-cell proliferation and enables better tumor control in a human melanoma xenograft model
Effects of PD-1:28 tm expression in T cells in vivo was studied using a human melanoma xenograft mouse model based on NSG mice carrying established vascularized subcutaneous melanoma tumors formed by the SK-Mel23 melanoma line (Fig. 6A) . CFSElabeled TCR-D115/Mock or TCR-D115/PD-1:28 tm T cells were injected intratumorally into tumors (802 mm 3 AE 83, mean AE SEM) and analyzed at 4 h, 1, 2, 4, 6 and 10 d after ATT by flow cytometry. It was observed that TCR-D115/Mock T cells stained positive for PD-1 on 1, 2, and 4 days after ATT. Thereafter, PD-1 staining decreased, but never completely disappeared ( Fig. 6B and  C) . This temporary expression of endogenous PD-1 suggests that T-cell activation occurred within the tumor microenvironment, as PD-1 is expressed on recently activated T cells (30) . Activation lasted until day 4 after ATT. For TCR-D115/PD-1:28 tm T cells, temporary expression of endogenous PD-1 could not be distinguished from the transgenic PD-1:28 tm expression. However, a temporary increase in median FI of PD-1 was observed with similar kinetics.
TCR-D115/PD-1:28 tm T cells lost CFSE intensity more rapidly and strongly than TCR-D115-T cells without PD-1:28 tm ( Fig. 6D  and E) . The difference was significant at all time points (Fig. 6D) , indicating that TCR-D115/PD-1:28 tm T cells responded faster and stronger to antigen-specific stimulation in the tumor microenvironment than TCR-D115 T cells without the chimeric costimulatory receptor. Survival could not be assessed in this model as T cells were injected into large tumors to ensure establishment of a challenging microenvironment. Animal regulatory restrictions did not allow extension of the observation time. However, compared over 7 days (Fig. 6F) (Fig. 6G) . Higher T-cell numbers and better tumor control after ATT with TCR-D115/PD-1:28 tm T cells are consistent with results from the spheroid model (Fig. 4D) . Low T-cell numbers and high PD-L1 expression may explain the observed poorer tumor control through TCR-D115/Mock T cells, as PD-L1 on T cells has been described to inhibit T-cell expansion and function (31) . Furthermore, in a Matrigel-killing assay in situ over 2 days ( Fig. 7C and D) . However, the cytokine profile of TILs in the PD-1:28 tm -negative ATT was shifted toward Th2 þ Th17 cytokines compared with splenocytes that were dominated by Th1 cytokines (Fig.  7E and F) . PD-1 can inhibit Tc1/Th1 responses in the tumor microenvironment through SHP-2 (32) and, indeed, very high levels of PD-1 were observed among TILs (Fig. 7E, inset) . Thus, endogenous PD-1 induction in the tumor microenvironment might contribute to the Th2 polarization of TILs. TILs from mice having received ATT with mPD-1:28 tm -positive T cells had a more favorable Th1/Th2 balance with less Th2 þ Th17 cytokines compared with TILs from mice given mPD-1:28 tm -negative ATT, yet with a notable increase in IL10.
Discussion
Immunotherapy has emerged as a pillar of cancer therapy, although improvements are needed as response rates are still low Depicted is the mean of two experiments þ SD. Two-way ANOVA, Ã , P < 0.05; ÃÃ , P < 0.01. n.s., nonsignificant.
(Continued.) Depicted is the amount of cytokine secreted by 25,000 CD8 þ cytokine secretion and degranulation and supports TCR-independent programs downstream of AKT/mTOR, such as survival, cellcycle progress, glucose consumption, and restoration of lytic proteins, which are particularly valuable in a restricting environment (23, 24) . Human CD8 þ T cells lose CD28 costimulatory receptor expression during effector-cell differentiation (34) , and epithelial cancers generally do not express cognate ligands CD80 or CD86 (35, 36) ; thus, T cells are unable to receive proper costimulation in this situation. In the context of ATT, low-avidity T cells may not be sufficiently active for tumor elimination due to low functional responses. Yet, they represent the majority of antitumor-reactive T cells and are relatively resistant to the suppressive tumor environment (13, 37) . Harnessing them for the antitumor response would enlarge and enrich the spectrum of T cells for ATT. As previous data have shown that PD-1:28 receptors can improve TCR-and chimeric antigen receptor (CAR)-engineered T cells (25, 26, 38, 39) , we engineered low-avidity T cells with a PD-1:28 chimeric signaling receptor to explore whether their functional activity could be enhanced allowing their inclusion in a library of TCRs for ATT. We show that PD-1:28 chimeric receptor can be stably expressed on the surface of human T cells. Surprisingly, the CD8 tm -linker destabilized surface expression, although similar sequences are effectively used in expression constructs of CAR receptors. We demonstrate that ligation of PD-1:28 overcomes important hurdles in ATT. PD-1:28 engineering invigorated TILs that were functionally disabled in human RCC environments. These TILs recovered Th1-cytokine secretion without unleashing Th2 or IL10 programs presumably based on restoration of ERK and AKT pathways as shown in our in vitro coculture system and previous work using similar receptors (25, 26) . PD-1:28 ameliorated T-cell inhibition that involved native PD-1/PD-L1 interactions and induced the costimulatory signaling pathway. The combined effect was stronger on the low-avidity TCR-D115-T cells compared with the high-avidity TCR-T58-T cells. Indeed, PD-1:28 cosignaling upgraded lowavidity TCR-D115-T cells to approximate cytokine and cytotoxic response levels of high-avidity TCR-T58-T cells. Thus, PD-1:28 engineering should allow harnessing the advantages of low-avidity T cells for the antitumor response.
PD-1:28 engineering enhanced the T-cell effector response against melanoma, RCC, squamous cell carcinoma, and glioblastoma cell lines. Response enhancement depended on PD-L1 surface expression level on the tumor cells. Thus, PD-1:28 engineering will deliver benefit in conditions with high PD-L1 expression, that is, in tumor milieus. Further evidence that PD-1:28 tm engineering can support T cells in a "hostile" tumor microenvironment was provided by a human xenograft model using large SK-Mel23 tumors with established T-cell-inhibitory conditions. Here, as was observed in SK-Mel23 spheroids, PD-1:28 tm -engineered low-avidity TCR-D115-T cells proliferated significantly more and reached higher absolute cell numbers compared with TCR-D115-T cells without the chimeric receptor. TCR-D115/PD-1:28 tm T cells also showed higher tumor cell killing. Proliferation and killing are important prerequisites for CD8 þ T cells to cause tumor shrinkage (19, 40, 41) . Tumors injected with low-avidity D115/PD-1:28 tm T cells grew slower over 7 days than tumors injected with TCR-D115 T cells. In future the xenograft animal experiments will be extended to larger sample sizes with longer observation times based on regulatory authority approval.
To determine the potential effect of PD-1:28 tm on tumor progression, a murine model of autochthonous HCC was used where tumors develop after activation of the SV40-TAg (28) . This tumor model resembles the human situation in its slow course of tumor progression, spanning up to 35 weeks from initiating the oncogenic process until death from tumor load. ATT using T cells engineered with a murine PD-1:28 tm showed positive effects on Tcell polarization. Most notable was the prevention of Th2 and Th17 cytokine secretion. The reduction of Th2 cytokines may be attributed to PD-1:28 tm deflecting native Th2-polarizing PD-1/ PD-L1 interactions into Th1-favoring costimulatory pathways. Similarly, augmentation of Th1 cytokines was observed in patients treated with PD-1 blockade (41) . ATT with PD-1:28 tm -positive T cells also resulted in more IL10, which may enhance cytotoxicity and IFNg secretion by CD8 þ T cells and tumor growth, but may also suppress antitumor immunity (42, 43) . Despite positive effects of PD-1:28 tm on T-cell performance in ATT, this was not sufficient to change tumor growth characteristics in this murine tumor model. Effects on tumor growth have been documented in a mouse model with subcutaneous tumors overexpressing an artificial antigen (ovalbumin) and PD-L1 (44) . In our model with tumor development over an extended time period using native antigen and PD-L1 expression, the tumor immune escape may be more complex (45) . Overcoming suppression likely requires additional supportive measurements beyond PD1:28 chimeric receptors, such as inhibition of IL10. This is in line with clinical results of ATT using TILs where benefit was achieved only after patient preconditioning with lymphodepletion and radiation in a multiple TIL injection regimen and coadministration of IL2 (19, 46) . We have noted that much higher T-cell numbers can be recovered from xenograft tumors after 7 days when IL15 is administrated intraperitoneally at the day of ATT (data not shown).
In summary, we show that cytokine secretion of functionally disabled human TILs can be restored through a PD-1:28 tm receptor. PD-1:28 tm mediated a functional upgrading of low-avidity T cells to the level seen in high-avidity T cells. As a consequence, low-avidity T cells previously considered to be therapeutically inefficient can now be considered for ATT. As the PD-1:28 engineering does not modify the TCR sequence, adverse effects on specificity are not expected, thus making this a safer approach than TCR affinity enhancement (3, 4, (10) (11) (12) 47) . PD-1:28 chimeric receptors have wider potential applications also for CAR-expressing T cells, where these engineered cells have shown better migration and tumor infiltration (38) . Although some benefits on T-cell function and tumor control were observed, more advanced in vivo models are needed to better document an improved antitumor response. It may be that the potential impact of PD-1:28 receptors on tumor control cannot be reliably visualized in a murine system (48) as mouse T cells do not lose CD28 (34, 49) and, therefore, may not share the same necessity of facilitated costimulation with human T cells. Moreover, mouse models often fail to correctly predict clinical efficacy. New models, such as advanced tumor spheroid 3D cultures, may be helpful in this regard.
Checkpoint inhibition therapies using PD-1/PD-L1 antibodies may benefit from a combination with PD-1:28-engineered T-cell therapy as therapeutically applied anti-PD-L1/anti-PD-1 antibodies may not reach saturation of all target molecules (50) . The supportive effects of PD-1:28 engineering imparted on T-cell function make it an attractive tool for ATT.
